Volz H P, Müller H, Sturm Y, Preussler B, Möller H J
Psychiatric University Hospital Bonn, Germany.
Psychiatry Res. 1995 Sep 29;58(2):107-15. doi: 10.1016/0165-1781(95)02654-f.
Most findings of antidepressant treatment prediction have not been replicated, and this applies to biological predictors as well as sociodemographic and early course predictors. One exception might be early psychopathological improvement. To reevaluate this question, we examined the results of two large-scale controlled clinical trials comparing the selective and reversible inhibitor of monoamine oxidase type A (MAO-A) brofaromine with the standard tricyclic compound imipramine. One trial was carried out in a normal-aged patient group; the other, in elderly patients. Above all, we were interested in determining whether early treatment course would prove predictive of later outcome. The main finding was that the initial antidepressant effect (measured after 1 and 2 weeks) predicted longer term outcome. Although this association was not as strong in the elderly patient group, its predictive value did possess a certain clinical relevance.
大多数抗抑郁治疗预测的研究结果都未能得到重复验证，这在生物学预测指标以及社会人口统计学和早期病程预测指标方面均是如此。一个例外可能是早期精神病理学改善情况。为了重新评估这个问题，我们研究了两项大规模对照临床试验的结果，这两项试验比较了A型单胺氧化酶（MAO - A）的选择性可逆抑制剂溴法罗明与标准三环化合物丙咪嗪。一项试验在正常年龄患者组中进行；另一项在老年患者中进行。最重要的是，我们感兴趣的是确定早期治疗过程是否能预测后期结果。主要发现是初始抗抑郁效果（在1周和2周后测量）可预测长期结果。尽管这种关联在老年患者组中不那么强烈，但其预测价值确实具有一定的临床相关性。
